School of International Business, China Pharmaceutical University (CPU), China
This presentation offers a comparative overview of drug reimbursement policies for anticancer therapies across Asia and France, with a particular focus on oncology. Drawing on large-scale health insurance databases and electronic health record (EHR) systems, our team examines how reimbursement criteria and pharmaceutical benefits are shaped by real-world evidence, including safety profiles and treatment efficacy observed in patient cohorts. We aim to highlight key similarities and differences across health systems, and to discuss implications for policy and clinical practice
host: Prof E. DESHAYES (ICM)
Situé dans le Parc Euromédecine, l'Institut de Recherche en Cancérologie de Montpellier (U1194) est localisé sur le Campus Val d'Aurelle (ICM, Institut régional du Cancer Montpellier / Val d'Aurelle).
Centre de Recherche U1194 soutenu par l'Inserm, l'Université de Montpellier et l'Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de
